Jump to content

Stock indices to Top out in Sept - Nikkei shows the way.

Recommended Posts

So 30 Aug didn't work out, I'm not surprised my confidence level was low because it didn't fit my big picture targets but each failure adds to the overall picture and I have a new possibility that does fit with those targets and with credible EWT counts and several classic charting formations.  Calling the top is still a stretch and one would want to see confirmation before risking anything other than a speculative anticipatory short trade but I like to set up road maps that follow a charting logic and see how closely the market follows them; the closer they follow the higher my confidence level becomes so let's see...


The Nikkei is the one that is really strong for me because it is not a market top but just a retrace; a higher level of confidence may be inferred on a retrace than a clear water top because there is past higher price action to draw upon so lets start with that.  On the assumption that all these markets are now inextricably linked, and I believe they are by global economic conditions and more particularly central bank policy.


The Weekly chart shows a strong head & shoulders formation around the Jun/Aug 2015 Top (could also be described as a double top but that is a bit of a stretch because it is not wide enough in time for comfort).  The H&S neckline was broken in early Jan 2016, retested in late Jan and again in April and is now heading for another test.  For EWT proponents the count is large scale 1-2 (purple) after the top followed by a 1-2 (Pink) retrace as part of Wave 3 down.


Now looking at the Daily chart you can see the 1-2 (pink) retrace move in close up.  It is currently running in an EWT complex retrace pattern (blue A-B-C labels) or a larger classic A-B-C (red labels) all of which suggests strongly that this is indeed a retrace move rather than a motive (1-5 pattern).  If correct the market is in a final run up from 24 June in a wave C, which exhibits both an A-B-C and 1-5 pattern (this means the classic and complex retrace forms can both apply but that doesn't matter as they both point to a retrace move that will conclude at the same point).  The most likely conclusion is the 62% Fib level, which also cuts both the Neckline from the weekly H&S and a Triangle on the daily (this top line has excellent price touches both before and after the June 2016 low, the before ones being so-called prior pivots giving this line very good resistance credibility).  With strong Neg Mom Div building and both RSI and Stochastic heading into over bought territory I have a fairly high confidence level with this set up.  It remains to be seen if the 4 hourly and hourly charts offer additional signals for a retrace reversal as we get into the end of the month.


Alas the Triangle top line on the Daily can be drawn in a number of positions, as usual, but the 2 that I like show hits on the various retrace resistance lines at some point in the last 2 weeks of September.  Hopefully this will get narrowed down as we approach the end of the month.


I will post on the other stock indices separately, which show corroborating analysis.


Link to comment
  • 4 weeks later...

Yeh i just noticed that as i was reading it, we already surpassed it. Although a credible scenario, i think this now shows that HSBC's alternative W-count is now invalidated. Seems like OPEC it was willing to come to a conclusion this afternoon. USD CAD worked out quite well, took ages for the drop but finally happened. But hedge funds still maintain a bearish view and appears that this was largely short-covering. It seems Saudi Arabia are starting to realise they dont have the dominante force they used to have, once oil surpasses 50-60 shale producers will have a greater incentive to just switch on the taps again. I dont think it is going to be a pretty end of the year for 2016. Watch closely lol. 

Link to comment

I prefer to watch the S&P to determine the top of this market , it being the largest market and if you look at it there is a similar H&S and neckline as on the Dow but the neckline has been well punctured for the second time this afternoon while the Dow is only at the neckline for the second time.  I don't know why the media and analysts focus so much on the Dow when the S&P is the all important market...  Anyway the S&P has a more bullish stance to me but we will need to see it break the Triangle and until it does the scenarios remain at 50/50 for me.


Link to comment

Mercury you now how the likes of Bloomberg and CNBC are like, DOW is all to them haha. Mind you its better than the BBC, who commented 2 days ago that the reason bank shares where down was because of Brexit, not one mention of Deutsche. So typical, mind you SKY is just as bad all pro-remainers. I was however worried with my analysis on the DOW however few days back as it was making a significant retrace which made me question if we where still on a pull back. But appears that we are not for now. I think like with all W-5's is that their impulse moves seem for delicate and less vigorous than their counterparts, but that could me lol. Onwards and upwards for now.

Link to comment

LOL!  Yes you are right about the MSM .  I don't know whether it is political bias; sheer incompetence or just headline grabbing but they never seem to get their reasoning right.  They remind me of children who come up with the most bizarre of reasoning for things and never look beyond the obvious, which is usually wrong...  Cognitive Dissonance; Confirmation Bias, egocentricity, take your pick: Post Hoc Ergo Propter Hoc!


Anyway, back to the technicals, I was looking at the Nasdaq to see if I could use it as a gauge, it being the most buoyant of the US large Caps and with the most outlandish P/E ratios, and there was an interesting note from John Burford (tramlinetraders.com) where he suggested a quite hefty rally phase now (behind further CB actions I guess) but after a short EWT1-2 retrace off the Sept 22 high.  [Now I don't want to misrepresent him (having got the slap down for that recently) so to be clear this is my interpretation of what he was saying so check it for yourselves].  I don't agree with him at this point, although I can see the technical scenario.  If we do see a clear 1-2 retrace off the Sept 22 high then I would have to look at this again.


For now my bias (and it is a bias so watch out!) is for a further final run up to a conclusion BUT I don't think the run up will be clean, rather a slow crablike sideways grind up, probably in an ending Diagonal/Triangle form.  I expect this to be filled with whiplash moves and, for me at least, not worth trading.


So in conclusion 2 main scenarios seem to be prevalent:

  1. That slow grind up to a conclusion, which for me fits with the current uncertainty over the economy in general, what the Fed really mean to do re rates and a likely disappointing Q3 earnings season, never mind geopolitical events
  2. A short EWT1-2 retrace off the Sept 22 high as part of a long strong rally in large scale wave 3 up to who knows where behind ongoing central bank madness (can't rule it out thought can we...!)

Clearly a fresh higher high above Sept 22 level without that EWT1-2 would result in a strong leaning towards scenario 1.  Let's see...







Link to comment

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • General Statistics

    • Total Topics
    • Total Posts
    • Total Members
    • Most Online
      10/06/21 10:53

    Newest Member
    Joined 27/07/21 15:11
  • Posts

    • GlaxoSmithKline Q2 revenue is expected to show revenue growth from newer drugs partially offset by increased generic competition in older drugs. Source: Bloomberg   Shares GlaxoSmithKline Price Revenue Vaccine Earnings before interest, taxes, depreciation and amortization  Shaun Murison | Senior Market Analyst, Johannesburg | Publication date: Tuesday 27 July 2021  When is GlaxoSmithKline earnings date? The GlaxoSmithKline (GSK) earnings release date is scheduled for the 28 July 2021. The scheduled results will cover the groups second quarter and half-year earnings.   GSK results preview: What does the street expect? While GlaxoSmithKline (in partnership with Sanofi Pasteur) look to stage three trials of their Covid-19 vaccine, the company has not yet released a vaccine to market. The global rollout of Covid-19 vaccines (by competitors) looks to have disrupted the course of other vaccine programmes in key markets such as the US and the UK for GSK. Revenue for second quarter (Q2) 2021 is expected to be bolstered by sales of newer drugs in the respiratory and HIV segments, with a partial offset from older drugs which are finding increased competition through generic offerings. In terms of the upcoming results, a mean of analyst estimates compiled by Refinitiv data arrive at the following: Revenue $10.433 billion (+10.27%) year on year (YoY) Earnings before interest tax depreciation amortisation (EBITDA) $2.855 billion (-8.91% YoY) Earnings per share (EPS) $0.51 (+10.87% YoY) How to trade the GlaxoSmithKline results   Source: Refinitiv   A Refinitiv poll of analyst ratings arrive have a long term consensus rating of ‘buy’ for GlaxoSmithKline with a target price $47.87. GlaxoSmithKline (ADR) share price: technical analysis   Source: IG The share price of GlaxoSmithKline continues to trade in an uptrend which has been in place since the beginning of March 2021. The price has however started to correct from near term highs. The correction sees the price now testing support at the 38.85 level. Traders looking for long entry might prefer to see a bullish price reversal around current levels accompanied by a sharper move out of oversold territory by the Stochastic oscillator. In this scenario, the recent high at 40.55 would become the initial resistance target, while a close below 38.35 could be used as a stop loss consideration for the trade. However should a bullish price reversal not manifest and we see the price move to close below both the 38.85 and 38.35 support levels, this could instead be a suggestion that the uptrend has failed and perhaps a new downtrend for the share price is forming. In Summary GSK reports Q2 2021 results on the 28 July Q2 revenue of $10.433 billion (+10.27% YoY) is expected Q2 EBITDA of $2.855 billion (-8.91% YoY) are expected EPS $0.51 (+10.87% YoY) in the Q2 are expected The average long term broker rating for GSK is a ‘buy’ The share price of GSK is testing support as it finds itself in a short-term correction of a longer-term uptrend
    • Alibaba continues to enjoy strong revenue and customer growth, but the decline in its stock price reflects a bleaker outlook thanks to the actions of the Chinese government. Source: Bloomberg   Shares Alibaba Group China Investor IPO Price  Chris Beauchamp | Chief Market Analyst, London | Publication date: Tuesday 27 July 2021    When is Alibaba’s earnings date? Alibaba reports earnings on 3 August, covering its fiscal first quarter (Q1). Alibaba earnings – what to expect Alibaba is expected to report revenue of $32 billion, with earnings per share of $2.24. Alibaba continues to enjoy excellent growth, achieving one billion customers in the 2021 financial year (FY2021), with the vast majority of these based in China. Profit margins and revenues have risen at a steady pace in every year since 2013, at 10% and 23% respectively. However, for Chinese tech shares such as Alibaba, the main concern is no longer business performance, but the attitude of the Chinese government instead. The cancellation of the Ant Financial initial public offering (IPO) and the current clampdown on tutoring stocks points towards a much more restrictive approach to the private sector. As many could have predicted, the culture clash between free market capitalism and the controlling instincts of the Chinese Communist Party has begun anew, with the Party determined to rein in the perceived excesses of the free market. This is a situation unfamiliar to many investors, unused to the impact of government interference on most companies except in relatively isolated circumstances, and accounts for the underperformance of Chinese shares, with Alibaba no exception. Find out more on how to buy, sell, and short Alibaba shares Alibaba broker ratings A total of 17 analysts currently rate Alibaba as a ‘strong buy’, with 30 more at ‘buy’. Three analysts have a ‘hold’ rating, and only one ‘sell’. Alibaba stock – technical analysis The direction in Alibaba stock is clear for the time being. Rallies have been regularly sold, with the latest bounce in late June running into the 100-day simple moving average (SMA), currently 22,225. With the macro outlook so unfavourable the stock continues to reflect investor caution, so it looks like further declines are on the cards as the price targets 18,000 and lower.   Source: ProRealTime A solid business, but outlook continues to darken Alibaba has plenty to commend it from a fundamental perspective, but with Beijing adopting an activist position the stock continues to decline. Investors might argue that this means Alibaba is becoming a bargain, but traders will want to see a turnaround in the price, which is unlikely to happen unless the Chinese government reduces its interventions.
    • EUR/USD, GBP/USD and NZD/USD weaken from Fibonacci resistance EUR/USD, GBP/USD and NZD/USD turn lower after posting a deep 76.4% Fibonacci retracement.   Forex NZD/USD EUR/USD GBP/USD Pound sterling Euro    Joshua Mahony | Senior Market Analyst, London | Publication date: Tuesday 27 July 2021  EUR/USD turning lower from latest retracement EUR/USD has managed to post yet another 76.4% Fibonacci retracement, with the pair heading lower once again. This highlights how the trend seen over the course of the past two months remains worth following. While the trend is very shallow in nature, that does bring a higher likeliness of a deep retracement. As such, a bearish outlook holds from here, with a push up through the prior swing-high of $1.183 required to negate that downside bias. Source: ProRealTime GBP/USD turning lower after 76.4% retracement GBP/USD has started to lose ground in early trade today, following the rally into the 76.4% Fibonacci resistance level at $1.383. With a wider bearish trend playing out over recent months, there is a good chance we see further downside from here. A rise up through the $1.391 level would be required to negate that outlook. Source: ProRealTime NZD/USD slumps after deep pullback NZD/USD has similarly turned lower after a 76.4% Fibonacci retracement yesterday. The wider downtrend points towards such a move coming into play, with a rise through $0.7045 required to negate that bearish outlook. Until then, further weakness looks likely from here. Source: ProRealTime
  • Create New...